Novartis’ Certican Renal Toxicity Reduction To Be Reviewed By Cardio-Renal Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company claims ex-U.S. clinical experience is enough for U.S. approval of Certican to prevent heart transplant rejection.